| HOME >> BIOLOGY >> TECHNOLOGY |
l Property
Ester's patent estate protects its novel technology platform with both issued patents and pending patent applications. EN101 is protected by an issued composition of matter patent in the United States that runs to 2022, and has patent protection pending in a number of other jurisdictions around the world, including Europe.
Technology Platform
Ester's therapeutic platform is based on novel and proprietary discoveries in the field of acetylcholinesterase ("AChE"), developed by Professor Hermona Soreq of the Hebrew University of Jerusalem. AChE is a degrading enzyme of the neurotransmitter acetylcholine, the imbalance of which plays a central role in a range of currently incurable and highly debilitating neurodegenerative conditions. The basic premise of Ester's therapeutic paradigm is the modulation of the "read-through" isoform of acetylcholinesterase ("AChE-R"), an excess of which plays a fundamental detrimental role in the CNS and inflammatory processes.
Ester's technology platform also exhibits anti-inflammatory effects, including an indirect inhibitory effect on key pro-inflammatory cytokines via modulation of AChE-R, as well as a direct anti-inflammatory effect via modulation of macrophage activity mediated by interaction with the toll-like receptor or TLR signalling pathway.
Ester Integration
Preparations for the integration of Ester and Amarin have already begun. Amarin is not acquiring any facilities or office space in Israel. The management of Ester's programs and research and development activity is being transitioned to Amarin's research and development team in Oxford, England. To facilitate this transition to Amarin, Eli Hazum, Chief Executive Officer of Ester, will act as a consultant to Amarin for a period of at least six months.
Acquisition Consideration
Under the terms of the acquisition agreement, Amarin will acquire 100%
of the issued share capital of Ester for initial consideration
'/>"/>
| SOURCE Amarin Corporation Plc Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
2. Amarin to Present at 4th Annual Bio Investor Forum
3. Amarin Announces Initiation of Cardiovascular Development Strategy
4. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
5. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
6. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
7. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
8. Monsanto Company Signs Share Subscription Agreement With Devgen
9. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
10. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
11. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |